Cytokinetics (Cytokinetics) 3-Year Dividend Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics 3-Year Dividend Growth Rate?

Cytokinetics's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The historical rank and industry rank for Cytokinetics's 3-Year Dividend Growth Rate or its related term are showing as below:

CYTK's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 14.15
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Cytokinetics's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Cytokinetics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Cytokinetics's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Cytokinetics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytokinetics's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Cytokinetics's 3-Year Dividend Growth Rate falls into.

Cytokinetics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Cytokinetics (NAS:CYTK) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Cytokinetics's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-1.33
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytokinetics 3-Year Dividend Growth Rate Related Terms>

Cytokinetics (Cytokinetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (NAS:CYTK) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

KK3A:Germany

Address

350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.cytokinetics.com

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Executives

Robert I Blum	officer: EVP, Corp. Development & CBO	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John T Henderson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Fady Ibraham Malik	officer: SVP Research & Early Dev	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Wendall Wierenga	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Robert Wong	officer: VP, Chief Accounting Officer	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Ching Jaw	officer: SVP Finance & CFO	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Sandford D Smith	director	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
B Lynne Parshall	director	2855 GAZELLE COURT, CARLSBAD CA 92010
Santo J Costa	director
Kaye Edward M. Md	director	3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Robert Arthur Harrington	director	C/O CYTOKINETICS, INCORPORATED, 350 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Mark A Schlossberg	officer: SVP - Legal & General Counsel	C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
David Cragg	officer: V.P., Human Resources	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
L Patrick Gage	director	C/O NEOSE TECHNOLOGIES, 102 WITMER RD, HORSHAM PA 19044